MSL
SAGE

Mackay Shields LLC’s Sage Therapeutics SAGE Stock Holding History

Mackay Shields LLC’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-12,638
Closed -$1.98M – 1217
2018
Q2 		$1.98M Hold
12,638
– – 0.01% 771
2018
Q1 		$2.04M Buy
+12,638
New +$2.15M 0.01% 782

Other funds holding SAGE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Mackay Shields LLC's SAGE Position: Q3 2018 in Review

Mackay Shields LLC sold out of Sage Therapeutics (SAGE) in Q3 2018, closing a stake of 12,638 shares — an estimated $1.98M sold.

Mackay Shields LLC first reported a position in SAGE in Q1 2018 and held it in 2 quarters. The position peaked at $2.04M in Q1 2018. 275 funds tracked by Wall St. Rank hold SAGE as of Q3 2018.

  • Mackay Shields LLC reported no remaining Sage Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Mackay Shields LLC sold 12,638 Sage Therapeutics shares in Q3 2018, an estimated $1.98M.
  • Mackay Shields LLC first reported a position in Sage Therapeutics in Q1 2018 and held it in 2 quarters.
  • Mackay Shields LLC's Sage Therapeutics position peaked at $2.04M in Q1 2018.
  • 275 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2018.

Based on Mackay Shields LLC's 13F filing for Q3 2018, filed 14 Nov 2018.